KNOXVILLE, Tenn.--(BUSINESS WIRE)--Enigma Biomedical USA, Inc (Enigma) and the University of Wisconsin-Madison (UW-Madison) today announced formation of a partnership focused on development of next-generation Positron Emission Tomography (PET) Imaging and fluid biomarkers. Enigma will support this work at the new Biomarker Development Lab for Age-related Neurodegenerative Disease at the UW School of Medicine and Public Health in Madison, WI. Enigma's Chief Scientific Officer, Hartmuth Kolb, Ph.
UW–Madison is a Wisconsin-based educational institution that offers undergraduate, master and doctoral programs in disciplines such as astronomy and biochemistry for students.